Video Experimental Relacionado
Updated: Jun 13, 2026
11:33
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
Published on: March 12, 2013
El bloqueo selectivo de los canales de potasio molecular previene la fibrilación auricular
Guy Amit1, Kan Kikuchi, Ian D Greener
1Heart and Vascular Research Center, MetroHealth Hospital, Case Western Reserve University, Cleveland, OH 44109, USA.
Circulation
|May 19, 2010
Resumen
La terapia génica con KCNH2-G628S evitó con éxito la fibrilación auricular (FA) en cerdos al prolongar el potencial de acción auricular. Sin embargo, este efecto terapéutico fue transitorio y se correlacionó con los niveles de expresión transgénica.
Área de la Ciencia:
- Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
- Terapia génica Terapia génica La terapia génica es una terapia genética.
- Electrofisiología y electrofisiología.
Sus antecedentes:
- Las terapias actuales para la fibrilación auricular (FA) se enfrentan a limitaciones de seguridad y eficacia.
- La AF a menudo es impulsada por mecanismos de reingreso.
- Dirigirse a la electrofisiología auricular a través de la transferencia génica ofrece un nuevo enfoque terapéutico.
Objetivo del estudio:
- Investigar el potencial de la transferencia de genes auriculares para prevenir la FA mediante la manipulación de la electrofisiología auricular.
- Evaluar la eficacia de un mutante negativo dominante de la subunidad del canal de potasio I(Kr) (KCNH2-G628S) en la prevención de la FA.
Principales métodos:
- La transferencia génica atrial epicárdica mediada por adenovirus de KCNH2-G628S en un modelo de AF porcino.
- Evaluación del ritmo cardíaco, electrofisiología y cambios moleculares después de la transferencia.
- Comparación entre los animales de control y los que recibieron la transferencia de genes KCNH2-G628S.
Principales resultados:
- Los animales que recibieron la transferencia de genes KCNH2-G628S mostraron una reducción significativa en el riesgo relativo de FA (0,44, P<0,01).
- La duración del potencial de acción auricular se prolongó en los animales G628S, con un aumento de los niveles de proteína KCNH2.
- La eficacia terapéutica y la prolongación del potencial de acción disminuyen en el día 21 postoperatorio, lo que se correlaciona con la expresión génica reducida.
Conclusiones:
- La terapia génica con KCNH2-G628S eliminó efectivamente la AF al prolongar la duración del potencial de acción auricular.
- La duración del efecto terapéutico se correlacionó directamente con la persistencia de la expresión transgénica.
Videos de Conceptos Relacionados
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:28Depolarizing Blockers: Mechanism of Action
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...